Human end of 2014, Global Healthcare Group medicine (HG) India has voted publication list Top 10duoc phamhua least 2015. According to HG appointments, these are the "savior" rescue treatment, attend is to be put into commercial in 2015.

1. Keytruda

Early May 9/2014, Authority phamMy Food Pharmacopoeia (FDA) has approved drugs Keytruda (pembrolizumab) by Merck & Co. in New Jersey, USA, prepared, used to treat malignant tumor group progressed or not cut, do not use other medicines work. Keytruda the 6th therapy was approved by the FDA since 2011, including: ipilimumab (2011), peginterferon alfa-2b (2011), vemurafenib (2011), dabrafenib (2013), and trametinib (2013). Keytruda effectiveness of research based on 170 people showed shrinking tumors, treatment costs $ 12,500 / month. In addition to skin cancer, the drug also works for other cancers such as lung and kidney cancer.

2.Vacxinsot hemorrhage

7/2014 last month, the Group of French pharmaceutical Sanofi said it had successfully tested a vaccine containing serotypes 4 dengue virus (Dengue) in Thailand. According to the World Health Organization (WHO), an estimated 50% of the global population at risk of exposure to dengue. Results stage clinical studies showed that the vaccine is formally protection in 95.5% of patients and can weigh up to 80.3% risk of hospitalization. Expected to be available in the second half of 2015.

3. Sifalimumab

2015, in England, we will offer a drugs salable systemic lupus erythematosus (SLE), an autoimmune disease of unknown cause, characterized by the free-form appearance of antibodies against the antigen , these antigens directly destroy the cells and tissues of the body and finally born infection. Sifalimumab targeting interferon, a protein related to inflammation and improve health. Sifalimumab are either pharmaceuticals SLE treatment, including mavrilimumab and sifalimumab, all due to technology company AstraZeneca MedImmune biotechnology dosage.

4. LCZ696

LCZ696 combines two blood pressure medicines, an angiotensin II receptor blocker (ARB) and a neprilysin inhibitor, called sacubitril. Through experimentation showed remarkable LCZ696 than the standard ACE inhibitors in heart failure treatment. Especially, LCZ696 was well tolerated, and safe for patients. In trials funded by Novartis in 8400 patients with heart failure using enalapril showed LCZ696 or group LCZ696 reduced the risk of hospitalization for heart failure by 21% compared with enalapril. Of the 1,251 people who die from heart disease during the pilot will use LCZ696 558 (13.3%) and 693 using enalapril (16.5%). Novartis is currently evaluating FDA approval, is expected to be available in the market in late 2015.

5. Olysio

Johnson & Johnson has said, in 2015 to where they will be put into commercial drugs with chronic hepatitis C whose name Olysio (simeprevir), used in conjunction with Gilead Sciences Inc. Sovaldi This combination allows not have to use the standard therapy, including interferon, injected drugs have side effects like flu. Olysio protease inhibitors, blocking a particular protein necessary for replication of the hepatitis C virus protease inhibitor and the third received FDA approval to treat the hepatitis C virus after Victrelis (boceprevir) and Incivek (telaprevir ).

6. Nivolumab

Nivolumab its product is Bristol-Myers Squibb (UK) for the treatment of skin cancer (melanoma) help patients live longer compared to only chemotherapy. In trials in 107 patients, 80% had metastatic nivolumab injected intravenously 2 weeks / times in 96 weeks. The result, of the 33 patients tumor shrinkage of 50%, a number of cases the tumor disappeared completely, 7 people have stable health, that does not deteriorate during the half year. 43% of patients surviving 2 years, nearly 60% of patients survive one year. Currently, Bristol-Myers filed to the FDA for approval, and hope to have a specific decision in March 3/2015.

7. Kadcyla

Recently, the FDA has approved the drug trastuzumab emtansine kadcyla or ado-group for breast cancer had higher levels of the protein HER2 cancer cells highly positive. Kadcyla, its products Roche Holding AG (Switzerland) prepared after 15 years of research and testing. Suitable for groups of end-stage metastatic disease, the drug is not effective.

8. Palbociclib

Pfizer has conducted a series of studies on medicines for people with advanced breast cancer, known as PD 0332991. Palbociclib Palbociclib or used in combination with hormonal drugs Femara (Letrozole) for greater efficiency compared to only use Femara treatment in advanced breast cancer (stage IV) ER positive and HER2-negative. In essence Palbociclib is an inhibitor (CDK 4/6) to help prevent the cancer cells divide and grow. In the first study phase in 165 postmenopausal women diagnosed with advanced breast cancer, ER-positive and HER2-negative, were treated with Femara in combination with placebo (placebo) or in combination with palbociclib Femara. The result, the group treated with Femara in combination with palboliclib survived 20.2 months before tumors develop also the other group was only 10, 2 months. Pfizer is currently apply to the FDA for approval, is expected to be available in the second half of 2015.

9. OFEV

OFEV (nintedanib) is a product of Boehringer Ingelheim (Germany) has been FDA approved for the treatment of idiopathic pulmonary fibrosis (IPF), the disease so far has no cure. Through clinical trials showed that the drug led to slow the decline in lung function over 50%.

10. Cyramza

Drugmaker Eli Lilly of the US recently completed research staff, production and testing of new drugs called Cyramza, approved by the FDA last month for patients 4/2014 stomach cancer, cancer 5th popular 3rd in the world and the death rate. Cyramza used in combination regimens for patients with advanced gastric cancer or metastasis or before or after or fluoropyrimidine chemotherapy or a combination of Platinum. Cyramza an inhibiting agent, is effective "starves the tumor" by blocking the blood supply to tumors. Through testing, the drug is safe and highly effective. Those who used Cyramza prolonged median survival time of 5.2 months compared with 3.8 months in the placebo group.

Khac Nam (According DailyMail - 12/2014)